Genetic Diagnostics Company Wins Patent Lawsuit, Loses 2 Trillion Won in a Day

Natera Inc. (NASDAQ: NTRA) closed at $199 on the Nasdaq on the 8th, down 5.61% from the previous day, trimming its market value to about $28.2 billion (approximately ₩38 trillion). In a single trading session, it lost roughly $1.498 billion (around ₩2 trillion) in market capitalization, with 1,185,490 shares changing hands.

On April 6, the U.S. District Court for the District of Delaware handed Natera a favorable patent ruling, ordering rival Invitae to pay a 30% ongoing royalty on sales of certain minimal residual disease–related products. Natera also released data from a recent real-world study of circulating tumor DNA (ctDNA), showing that early ctDNA clearance was linked to a 96% three-year survival rate in MSI-H colorectal cancer patients. The company plans to present these findings at the AACR 2026 Annual Meeting in San Diego this April.

Headquartered in Austin, Texas, Natera is a clinical genetic testing company that offers precision-medicine services in oncology, women’s health and organ transplantation, based on noninvasive diagnostics using cell-free DNA in the blood. It is regarded as one of the leading U.S. genetic-testing stocks, having grown through noninvasive prenatal testing and residual-cancer detection assays such as Signatera.